ticlopidine and Death, Sudden, Cardiac studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)

Research Excerpts

Excerpt	Relevance	Reference
"In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance."	9.14	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009)
"Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention."	9.14	Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi ( Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD, 2009)
"High residual platelet reactivity (RPR) on clopidogrel treatment has been associated with increased risk for ischemic events during follow-up in patients with acute coronary syndromes."	5.17	Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). ( Campo, G; De Palma, R; Guastaroba, P; Guiducci, V; Magnavacchi, P; Manari, A; Marino, M; Marzocchi, A; Saia, F; Sangiorgio, P; Taglieri, N; Tondi, S; Valgimigli, M; Varani, E, 2013)
"In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance."	5.14	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009)
"Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention."	5.14	Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi ( Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD, 2009)
"The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme."	4.90	Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014)
"Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel."	3.74	Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007)
"Nonsustained ventricular tachycardia (NSVT) is common after acute coronary syndrome (ACS) and a marker of increased risk of arrhythmogenic death."	2.82	Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bui, AH; Cannon, CP; Guo, J; Held, C; Himmelmann, A; Husted, S; Im, K; James, SK; Michelson, EL; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L, 2016)
" If the international normalized ratio (INR) was kept > 2 for a long period, by means of frequent check-ups and effective dosage adjustment, the chance of death, recurrent myocardial infarction or stroke was 30-50% lower than when acetylsalicylic acid only was used."	2.43	[Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives]. ( Brouwer, A; Verheugt, FW; Waskowsky, WM, 2005)
"Common aetiologies of sudden cardiac death in children include coronary anomalies, channelopathies, and cardiomyopathies."	1.42	Unusual cause of aborted sudden cardiac death in a teen athlete: homozygosity for the 4G allele of the plasminogen activase inhibitor type 1 gene. ( Batlivala, S; Knudson, JD; Phillips, SB, 2015)

Research

Studies (28)

Authors

Clinical Trials (20)

Trial Overview

Trial Outcomes

Composite Endpoint of Cardiac Death and Myocardial Infarction (Not Clearly Attributable to a Non-target Vessel)

Overall Stent Thrombosis, Defined as Definite and Probable Stent Thrombosis, According to the Academic Research Consortium (ARC) Definition

Death

Major Adverse Cardiac Event (MACE)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (10.71)	18.2507
2000's	15 (53.57)	29.6817
2010's	10 (35.71)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Saia, F	1
Marino, M	1
Campo, G	1
Valgimigli, M	3
Guastaroba, P	1
Taglieri, N	1
Tondi, S	1
Manari, A	1
Guiducci, V	1
Sangiorgio, P	1
Varani, E	1
Magnavacchi, P	1
De Palma, R	1
Marzocchi, A	1
Silber, S	1
Kirtane, AJ	1
Belardi, JA	1
Liu, M	1
Brar, S	1
Rothman, M	1
Windecker, S	1
Phillips, SB	1
Batlivala, S	1
Knudson, JD	1
Bui, AH	1
Cannon, CP	1
Steg, PG	1
Storey, RF	1
Husted, S	1
Guo, J	1
Im, K	1
James, SK	1
Michelson, EL	1
Himmelmann, A	1
Held, C	1
Varenhorst, C	1
Wallentin, L	1
Scirica, BM	2
Lee, SY	1
Hong, MK	3
Shin, DH	1
Kim, JS	1
Kim, BK	2
Ko, YG	1
Choi, D	1
Jang, Y	2
Kim, HS	2
Palmerini, T	2
Stone, GW	2
Della Riva, D	1
Benedetto, U	1
Bacchi Reggiani, L	1
Feres, F	1
Abizaid, A	1
Gilard, M	1
Morice, MC	1
Park, KW	1
Colombo, A	1
Chieffo, A	1
Sangiorgi, D	1
Biondi-Zoccai, G	1
Généreux, P	1
Angelini, GD	1
Pufulete, M	1
White, J	1
Bhatt, DL	1
Jolly, SS	1
Pogue, J	1
Haladyn, K	1
Peters, RJ	1
Fox, KA	2
Avezum, A	1
Gersh, BJ	1
Rupprecht, HJ	1
Yusuf, S	1
Mehta, SR	1
Morrow, DA	1
Wiviott, SD	1
White, HD	1
Nicolau, JC	1
Bramucci, E	1
Murphy, SA	1
Bonaca, MP	1
Ruff, CT	1
McCabe, CH	1
Antman, EM	1
Braunwald, E	1
Wang, ZJ	1
Zhou, YJ	1
Liu, YY	1
Yu, M	1
Shi, DM	1
Zhao, YX	1
Guo, YH	1
Cheng, WJ	1
Nie, B	1
Ge, HL	1
Jia, DA	1
Yang, SW	1
Yan, ZX	1
Migliorini, A	1
Valenti, R	1
Marcucci, R	1
Parodi, G	1
Giuliani, G	1
Buonamici, P	1
Cerisano, G	1
Carrabba, N	1
Gensini, GF	1
Abbate, R	1
Antoniucci, D	1
Moerenhout, CM	1
Claeys, MJ	1
Haine, S	1
Miljoen, H	1
Bosmans, JM	1
Vertessen, F	1
Kluppels, K	1
Van der Planken, M	1
Vrints, CJ	1
Schulz, S	1
Mehilli, J	2
Neumann, FJ	2
Schuster, T	1
Massberg, S	1
Valina, C	1
Seyfarth, M	1
Pache, J	1
Laugwitz, KL	1
Büttner, HJ	1
Ndrepepa, G	1
Schömig, A	3
Kastrati, A	2
Preobrazhenskiĭ, DV	1
Sidorenko, BA	1
Fettser, DV	1
Batyraliev, TA	2
Niiazova-Karben, ZA	1
Besnili, F	1
Boggon, R	1
van Staa, TP	1
Timmis, A	1
Hemingway, H	1
Ray, KK	1
Begg, A	1
Emmas, C	1
Ishikawa, K	1
Shalaev, SV	1
Mintz, GS	1
Lee, CW	1
Kim, YH	1
Lee, SW	1
Song, JM	1
Han, KH	1
Kang, DH	1
Song, JK	1
Kim, JJ	1
Park, SW	1
Park, SJ	1
Waskowsky, WM	1
Brouwer, A	1
Verheugt, FW	1
Schmitt, C	1
Dibra, A	1
Volmer, C	1
Schühlen, H	2
Dirschinger, J	1
Dotzer, F	1
ten Berg, JM	1
Berger, PB	1
Serebruany, VL	1
Finn, AV	1
Joner, M	1
Nakazawa, G	1
Kolodgie, F	1
Newell, J	1
John, MC	1
Gold, HK	1
Virmani, R	1
Jiménez-Quevedo, P	2
Sabaté, M	2
Angiolillo, DJ	2
Alfonso, F	2
Hernández-Antolín, R	2
SanMartín, M	1
Gómez-Hospital, JA	1
Bañuelos, C	2
Escaned, J	2
Moreno, R	2
Fernández, C	1
Fernández-Avilés, F	1
Macaya, C	2
Bernardo, E	1
Costa, MA	1
Palazuelos, J	1
Guzman, LA	1
Bass, TA	1
Fernandez-Ortiz, A	1
Simon, DI	1
Schmaier, AH	1
Pershukov, IV	1
Hadamitzky, M	1
Walter, H	1
Ulm, K	1
Weber, AA	1
Schrör, K	1
Holm, J	1
Hillarp, A	1
Erhardt, L	1
Berntorp, E	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128]		2,349 participants (Actual)	Observational	2008-08-31	Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]		1,492 participants (Anticipated)	Observational [Patient Registry]	2019-08-01	Recruiting
A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453]		1,516 participants (Actual)	Interventional	2008-07-31	Completed
The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940]		100 participants (Actual)	Interventional	2009-03-31	Completed
RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084]	Phase 4	2,292 participants (Actual)	Interventional	2008-04-30	Completed
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872]	Phase 3	18,624 participants (Actual)	Interventional	2006-10-31	Completed
A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary[NCT00251576]	Phase 3	4,497 participants (Actual)	Interventional	1999-11-01	Completed
Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280]	Phase 4	2,505 participants (Actual)	Interventional	2008-08-31	Completed
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802]		120 participants (Anticipated)	Interventional	2014-08-31	Not yet recruiting
A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study[NCT00986050]	Phase 4	907 participants (Actual)	Interventional	2006-01-31	Completed
A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145]	Phase 4	30 participants (Anticipated)	Interventional	2007-11-30	Completed
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265]		31 participants (Actual)	Interventional	2014-09-30	Completed
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465]	Phase 4	50 participants (Actual)	Interventional	2017-02-16	Completed
In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030]	Phase 4	77 participants (Anticipated)	Interventional	2006-08-31	Recruiting
The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204]		60 participants (Actual)	Interventional	2008-05-31	Completed
Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894]		0 participants (Actual)	Observational	2010-11-30	Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.)
Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837]		33 participants (Actual)	Observational	2014-12-31	Completed
Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949]		8 participants (Actual)	Interventional	2013-09-30	Completed
The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093]		280 participants (Actual)	Observational	2014-06-30	Completed
A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330]	Phase 4	40 participants (Actual)	Interventional	2016-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	percentage of participants (Number)
Cardiac Death or Target Vessel MI	4.2

Intervention	percentage of participants (Number)
Overall Stent Thrombosis (Definite and Probable-ARC)	0.9

Intervention	percentage of participants (Number)
Primary Enrollment Group	1.3

Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Stent Thrombosis (ST)

Intervention	percentage of participants (Number)
Primary Enrollment Group	5.5

Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months

Target Lesion Failure (TLF)

Intervention	percentage of participants (Number)
Primary Enrollment Group	0.1

Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months

Target Vessel Failure (TVF)

Intervention	percentage of participants (Number)
Primary Enrollment Group	4.7

Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Target Vessel MI

Intervention	percentage of participants (Number)
Primary Enrollment Group	6.3

Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months

In-stent Late Lumen Loss (LLL)

Intervention	percentage of eligible participants (Number)
Primary Enrollment Group	1.4

The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months

Percent of Patient With Target Lesion Failure(Major Secondary Endpoint)

Intervention	mm (Mean)
Zotarolimus Eluting Stent	0.13

Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months

In-Stent Percent Diameter Stenosis

Intervention	percentage of participants with TLF (Number)
Zotarolims Eluting Stent	4.0

In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months

Target Lesion Failure

Intervention	Percentage diameter stenosis (Mean)
1. Resolute - 12-13 Months	21.65
2. XIENCE V - 12-13 Months	19.76

Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Intervention	percentage of participants (Number)
1. Resolute - 12-13 Months	8.2
2. XIENCE V - 12-13 Months	8.3

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Intervention	Participants (Number)
TICAGRELOR	901
CLOPIDOGREL	1065

Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Intervention	Participants (Number)
TICAGRELOR	1290
CLOPIDOGREL	1456

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Intervention	Participants (Number)
TICAGRELOR	569
CLOPIDOGREL	668

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Major Bleeding Event

Intervention	Participants (Number)
TICAGRELOR	864
CLOPIDOGREL	1014

Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	961
CLOPIDOGREL	929

Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Intervention	Participants (Number)
TICAGRELOR	619
CLOPIDOGREL	654

Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Death From Any Cause

Intervention	Participants (Number)
TICAGRELOR	329
CLOPIDOGREL	341

Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Death From Vascular Causes

Intervention	Participants (Number)
TICAGRELOR	399
CLOPIDOGREL	506

Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Major or Minor Bleeding

Intervention	Participants (Number)
TICAGRELOR	353
CLOPIDOGREL	442

Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With MI Event

Intervention	Participants (Number)
TICAGRELOR	1339
CLOPIDOGREL	1215

Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	504
CLOPIDOGREL	593

Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Non-procedural Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	362
CLOPIDOGREL	306

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Stroke

Intervention	Participants (Number)
TICAGRELOR	235
CLOPIDOGREL	180

Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Intervention	Participants (Number)
TICAGRELOR	125
CLOPIDOGREL	106

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Intervention	Participants (Number)
TICAGRELOR	21
CLOPIDOGREL	16

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

Percent Stent Coverage

Intervention	Participants (Number)
TICAGRELOR	84
CLOPIDOGREL	51

Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
	85% up to 90% stent coverage	90% up to 95% stent coverage	95% or greater percent stent coverage
NIDDM Patients Receiving the Resolute Stent	0	1	0
Non-diabetic Patients Receiving the Resolute Stent	1	3	1

Article	Year
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European heart journal, 2014, Aug-01, Volume: 35, Issue:29 Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,	2014
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. European heart journal, 2017, 04-07, Volume: 38, Issue:14 Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid	2017
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases]. Kardiologiia, 2010, Volume: 50, Issue:5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D	2010
[Anticoagulant, antiplatelet agents]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 4 Topics: Anticoagulants; Aspirin; Death, Sudden, Cardiac; Dipyridamole; Drug Therapy, Combination; Heparin; H	2003
[Antiplatelet drugs in prevention of complications of arteriosclerotic diseases: it is necessary to move beyond aspirin]. Kardiologiia, 2003, Volume: 43, Issue:6 Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Therapy, Combination; Hu	2003
[Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives]. Nederlands tijdschrift voor geneeskunde, 2005, Jan-08, Volume: 149, Issue:2 Topics: Anticoagulants; Aspirin; Clopidogrel; Coumarins; Death, Sudden, Cardiac; Fibrinolytic Agents; Humans	2005
[Drug-eluting stent thrombosis and its pharmacological prevention]. Kardiologiia, 2007, Volume: 47, Issue:7 Topics: Aspirin; Clopidogrel; Death, Sudden, Cardiac; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Inci	2007
[Pharmacology of ticlopidine and clopidogrel in comparison with acetylsalicylic acid]. Der Internist, 1997, Volume: 38, Issue:11 Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Thrombosis; Death, Sudden, Cardiac; Humans	1997

Article	Year
Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). The American journal of cardiology, 2013, Sep-15, Volume: 112, Issue:6 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Angiography; Death, Sudden, Cardiac; Electrocar	2013
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. Arrhythmia and electrophysiology, 2016, Volume: 9, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Cause of Death; Clopidogrel; Death, Sudden, Ca	2016
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clinical research in cardiology : official journal of the German Cardiac Society, 2017, Volume: 106, Issue:3 Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relations	2017
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. European heart journal, 2009, Volume: 30, Issue:8 Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F	2009
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi Circulation, 2009, Jun-02, Volume: 119, Issue:21 Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel;	2009
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. European heart journal, 2010, Volume: 31, Issue:20 Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Clopidogrel; Deat	2010
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. European heart journal, 2005, Volume: 26, Issue:14 Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagu	2005
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. European heart journal, 2007, Volume: 28, Issue:16 Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death,	2007
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA Circulation, 1997, Apr-15, Volume: 95, Issue:8 Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality	1997
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin. Thrombosis research, 1999, Nov-01, Volume: 96, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca	1999

Article	Year
Unusual cause of aborted sudden cardiac death in a teen athlete: homozygosity for the 4G allele of the plasminogen activase inhibitor type 1 gene. Cardiology in the young, 2015, Volume: 25, Issue:7 Topics: Adolescent; Alleles; Aspirin; Athletes; Cardiac Catheterization; Clopidogrel; Death, Sudden, Cardiac	2015
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents. Heart (British Cardiac Society), 2009, Volume: 95, Issue:19 Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro	2009
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation, 2009, Dec-01, Volume: 120, Issue:22 Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cor	2009
Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP. American heart journal, 2010, Volume: 159, Issue:3 Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Vessels;	2010
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). European heart journal, 2011, Volume: 32, Issue:19 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Death, Sudden,	2011
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation, 2004, Feb-24, Volume: 109, Issue:7 Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona	2004
Acute coronary syndromes, response to clopidogrel, and worsened cardiovascular outcomes: the hen and the egg dilemma. European heart journal, 2007, Volume: 28, Issue:5 Topics: Clopidogrel; Death, Sudden, Cardiac; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors;	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007, May-08, Volume: 115, Issue:18 Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro	2007
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American College of Cardiology, 2007, Oct-16, Volume: 50, Issue:16 Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde	2007
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American College of Cardiology, 2007, Oct-16, Volume: 50, Issue:16 Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde	2007
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American College of Cardiology, 2007, Oct-16, Volume: 50, Issue:16 Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde	2007
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American College of Cardiology, 2007, Oct-16, Volume: 50, Issue:16 Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde	2007
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk. Journal of the American College of Cardiology, 2007, Oct-16, Volume: 50, Issue:16 Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car	2007

ticlopidine and Death, Sudden, Cardiac